Elicio Therapeutics, Inc.ELTXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank56
3Y CAGR+13.4%
5Y CAGR-8.6%
Year-over-Year Change
Research and development spending
3Y CAGR
+13.4%/yr
vs +16.8%/yr prior
5Y CAGR
-8.6%/yr
Recent acceleration
Acceleration
-3.4pp
Decelerating
Percentile
P56
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $24.85M | -26.2% |
| 2024 | $33.66M | +48.4% |
| 2023 | $22.68M | +33.0% |
| 2022 | $17.05M | -64.9% |
| 2021 | $48.61M | +25.0% |
| 2020 | $38.88M | +30.5% |
| 2019 | $29.79M | +225.5% |
| 2018 | $9.15M | +4568.7% |
| 2013 | $196008.00 | - |
| 2012 | $0.00 | - |